Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AB-201 in Advanced HER2 Positive Gastric/GEJ Cancer
NCT07333820Phase 1Not yet recruiting
- Sponsor
- Yonsei University
- Start
- Feb 2026
- Primary completion
- Jul 2026
- Modality
- Recombinant Proteins and Enzymes, CAR-NK Cells
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of AB-201 in gastric cancer (GC) and gastroesophageal junction cancer, sponsored by Yonsei University. Primary endpoint: Adverse Events at 18 months. Planned start Feb 2026; status: not yet recruiting.
02
Drugs
AB-201
03
Conditions
gastric cancer (GC)gastroesophageal junction cancer
Beyond the preview
Go deeper on NCT07333820.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07333820.